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Abstract
Background: The “Unfinished Agenda” of infectious diseases is of great importance to policymakers and research
funding agencies that require ongoing research evidence on their effective management. Journal publications help
effectively share and disseminate research results to inform policy and practice. We assess research investments to
United Kingdom institutions in HIV, tuberculosis and malaria, and analyse these by numbers of publications and
citations and by disease and type of science.
Methods: Information on infection-related research investments awarded to United Kingdom institutions across
1997–2010 were sourced from funding agencies and individually categorised by disease and type of science.
Publications were sourced from the Scopus database via keyword searches and filtered to include only publications
relating to human disease and containing a United Kingdom-based first and/or last author. Data were matched by
disease and type of science categories. Investment (United Kingdom pounds) and publications were compared to
generate an ‘investment per publication’ metric; similarly, an ‘investment per citation’ metric was also developed as
a measure of the usefulness of research.
Results: Total research investment for all three diseases was £1.4 billion, and was greatest for HIV (£651.4 million),
followed by malaria (£518.7 million) and tuberculosis (£239.1 million). There were 17,271 included publications, with
9,322 for HIV, 4,451 for malaria, and 3,498 for tuberculosis. HIV publications received the most citations (254,949),
followed by malaria (148,559) and tuberculosis (100,244). According to UK pound per publication, tuberculosis
(£50,691) appeared the most productive for investment, compared to HIV (£61,971) and malaria (£94,483). By type
of science, public health research was most productive for HIV (£27,296) and tuberculosis (£22,273), while phase I–III
trials were most productive for malaria (£60,491). According to UK pound per citation, tuberculosis (£1,797) was the
most productive area for investment, compared to HIV (£2,265) and malaria (£2,834). Public health research was the
most productive type of science for HIV (£2,265) and tuberculosis (£1,797), whereas phase I–III trials were most
productive for malaria (£1,713).
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Conclusions: When comparing total publications and citations with research investment to United Kingdom
institutions, tuberculosis research appears to perform best in terms of efficiency. There were more public health-
related publications and citations for HIV and tuberculosis than other types of science. These findings demonstrate
the diversity of research funding and outputs, and provide new evidence to inform research investment strategies
for policymakers, funders, academic institutions, and healthcare organizations.
Keywords: AIDS, Bibliometrics, Funding, Health policy, HIV, Infectious disease, Malaria, Publications, Research impact,
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Background
The “Unfinished Agenda” of infectious diseases is of
great importance to policymakers and funders of global
health. The Global Burden of Disease study reaffirms the
continuing high burden of communicable disease [1, 2].
The outbreak of Ebola in West Africa has illustrated the
challenges faced by WHO and individual countries in ef-
fectively managing transmission across national borders
and closing the gaps in global surveillance systems [3].
Peer-reviewed publications in academic journals – a
typical output for funded research – can help to effect-
ively disseminate the latest knowledge to policymakers,
clinicians and other health professionals to inform policy
and practice. Researchers at United Kingdom institu-
tions have been prolific at publishing manuscripts in
peer-reviewed journals [4]. Infectious disease is also a
common topic of scientific papers [5, 6], and the vast
majority of references within these papers are citing
other journal articles [7]. Previous research analysing the
returns from public research investment have concen-
trated on estimating the societal benefits received from
research in the case of cancer [8]; cardiovascular and
stroke research [9]; arthritis [10]; as well as from medical
research in general [11]. However, this study is one of
the first that directly links the publication return from
public research investment. Although there have been
criticisms of the emphasis applied to publishing in jour-
nals, and particularly in those with high impact factors
[12], journals remain an important medium to sharing
new knowledge and research findings. In addition, links
between GDP and research productivity [13, 14] illus-
trate a policy need to understand a nation’s return on in-
vestment as an indicator of economic competitiveness
and potential for growth.
The Research Investments in Global Health study [15]
has systematically analysed investments between 1997
and 2013 in infectious disease research, highlighting
funding levels by disease area [16], awarding body [17],
receiving institution [18], and the sex of the principal in-
vestigator [19]. A 2015 publication showed that publica-
tion numbers for pneumonia broadly increased over
time, with no clear relationship to changes in funding
[20]. Herein, we consider three major infectious diseases,
HIV, tuberculosis and malaria, and analyse individual
trends in research investment and published outputs.
We use a novel metric to assess the numbers of publica-
tions relative to research investments. We explore the
impact of investment and published outputs by analysing
citations for each disease area and by type of science.
Methods
Awards for infectious disease research were sourced
from the leading funders of infectious disease research
in the public and philanthropic sectors. The compilation
of the research investments data has been described in
detail elsewhere [16, 20], but briefly reiterated here – we
systematically examined investment data from 585
awarding bodies [21]. Data was obtained by searches on
the funder website, requesting data directly from the
funder, or searches on databases such as the National
Research Register (now-archived and owned by the De-
partment of Health) and ClinicalTrials.gov. Each down-
loaded study was examined for relevance to human
infection. We excluded symposium grants, studies purely
related to veterinary or plant infectious disease, and in-
frastructure grants unless there was clear emphasis on
use for human infectious disease.
Studies from 1997 to 2010 were categorised under one
of four types of science along the research pipeline –
pre-clinical, phase I–III trials, product development, and
public health research. In the updated analysis including
the years 2011–2013, a fifth category, cross-disciplinary,
was included in response to a perceived increase in
awards that encouraged research across more than one
type of science. Owing to resource constraints, this cat-
egory has not yet been retrospectively applied to the
1997–2010 dataset. Awards were also categorised under
a range of diseases and cross-cutting areas, including
specific infections such as HIV, tuberculosis and malaria.
Investment data across all years were adjusted for 2013
inflation, and awards in international currencies were
converted to UK pounds using the average exchange rate
in the year of the award.
Head et al. Health Research Policy and Systems  (2015) 13:63 Page 2 of 7
Publications data from 1997–2013 was extracted from
the Scopus database. Searches for article types were re-
stricted to original article, editorial or review. Keywords
searches were ‘AIDS’ OR ‘HIV’; ‘malaria’ OR ‘plasmo-
dium’; and ‘tuberculosis’ OR ‘Mycobacterium’. By coun-
try, results were restricted to ‘UK’. All available
information was downloaded into Excel spreadsheets,
and conditional formatting equations applied in Excel to
separate the list of authors into individual cells and thus
be able to filter for publications with a United Kingdom-
based first and/or last author. This criterion was used as
a surrogate marker of significant United Kingdom in-
volvement and thus presumed to be more comparable as
a measure of outputs from United Kingdom research in-
vestments. Amongst the data available for analysis were
publication title, abstract, article type, year of publica-
tion, journal title, and number of citations for each
paper. Each publication was individually read by one of
the authors and assessed for relevance to disease in
humans for HIV/AIDS, malaria and tuberculosis, and
grouped in one of the five types of science along the re-
search and development pipeline used in the research
investments categories (pre-clinical, phase I–III trials,
product development, public health, cross-disciplinary).
To reduce inter-observer error, random samples of
data were checked by a second author, with errors
corrected and disagreements settled by consensus; a
Cohen’s kappa score was calculated to measurement
levels of agreement using GraphPad software [22].
In order to compare investments, publications and cita-
tions, a ‘UK pound per publication’ and ‘UK pound per
citation’ metric was developed, across the three diseases
and by type of science. The sum of investments across
1997–2010 was divided by the number of publications or
citations from 1997–2013. Cross-disciplinary science was
excluded from these analyses. Microsoft Excel 2013 and
Stata V13 were used to assemble and analyse the datasets.
Results
The number of publications extracted from Scopus was
19,461 for HIV, 9,355 for tuberculosis and 15,173 for
malaria. Author categorisation produced 9,322 publica-
tions for HIV (47.9% of the initial number), 3,498 for tu-
berculosis (37.4%), and 15,173 for malaria (29.3%;
Table 1). Major reasons for exclusion included keywords
cross-cutting across different areas (e.g. ‘AIDS’ is also
found in studies discussing ‘hearing aids’) and publications
containing a United Kingdom author but not in first or
last position. The agreement between authors (Cohen’s
kappa) for categorisation was assessed as 0.88, rated as
‘very good’.
Summary funding data have been published previously
[16]. The total research investment (Table 1) for all three
diseases was £1.4 billion and was greatest for HIV
(£651.4 million), followed by malaria (£518.7 million)
and tuberculosis (£239.1 million). Research investment
per annum for each disease showed considerable
variation (Figure 1). By type of science for each disease
(Additional file 1), preclinical science received propor-
tionately the greatest funding followed by public health
and phase I–III, whereas product development awards
received the least funding. A small amount of funding
focused on cross-disciplinary studies across 2011–2013.
Proportionate quantities for public health research in-
creased for all infections in the later years of this dataset,
typically at the expense of preclinical research. Similar
findings were observed for publication and citation
numbers (Additional file 1).
There were 17,271 publications included for analysis
(Table 1; 9,322 for HIV, 4,451 for malaria and 3,498 for tu-
berculosis). The predominant type of science (Additional
file 1) was public health for HIV (62.9%) and tubercu-
losis (51.0%). Unlike research investments, publication
numbers for all infections typically showed a steady
increase year on year (Figure 2) from 793 in 1997 to
1,458 in 2013.
The total number of citations (Table 1) was 503,752 and
these showed more variability by year and a steady yearly
decline for all three infections after 2006 (Figure 3). HIV
publications received the most citations (254,949),
followed by malaria (148,559) and tuberculosis (100,244;
Table 1).
By investment per publication (Table 2), tuberculosis
(£50,691) appears the most productive area for invest-
ment, compared to HIV and (£61,971) malaria (£94,483).
By type of science (Additional file 1), public health was
most productive for HIV (£27,296) and tuberculosis
(£22,273), with phase I–III trials being the least product-
ive (£326,440 and £187,185, respectively). For malaria,
phase I–III trials were the most productive (£60,491)
and all other types of science highlighted between £93
and £96,000 of investment per publication.
By investment per citation (Table 3), tuberculosis
(£1,797) appears the most productive area for investment,
Table 1 Summary of total research investment, publication and citation numbers for tuberculosis, HIV and malaria
Variable HIV Tuberculosis Malaria Total
Investment 1997–2010, millions of UK pounds 515.7 168.0 381.5 1,065.2
Publications 1997–2013 9,322 3,498 4,451 17,271
Citations 1997–2013 254,949 100,244 148,559 503,752
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compared to HIV (£2,265) and malaria (£2,834). By type
of science (Additional file 1), public health was the most
productive for HIV (£2,265) and tuberculosis (£1,797),
with phase I–III trials being the least productive (£7,479
and £4,035, respectively). For malaria, phase I–III trials
were most productive (£1,713) and all other types of sci-
ence highlighted between £2,600 and £3,200 of investment
per publication.
Discussion
Across 1997–2013, significant public and philanthropic
investments of over £1.4 billion have been awarded to
United Kingdom institutions for HIV-, tuberculosis- and
malaria-related research, with the vast majority of invest-
ment (£1.1 billion; 80.2% of total) directed to preclinical
science or public health research. There were 17,271
published outputs on these disease areas, which were
cited on 503,752 occasions. The most published and
cited disease was HIV, and publications and citations
were most numerous in preclinical science for HIV and
tuberculosis, but for malaria this was phase I–III trials.
The ‘investment per publication’ and ‘investment per cit-
ation’ metrics show tuberculosis to be the most product-
ive area of research investment. By type of science, the
metrics suggest public health research to be the most pro-
ductive area for HIV and tuberculosis and phase I–III
trials for malaria. The publication trends show that publi-
cation numbers steadily increase over time, distinct from
the annual volatility of research funding.
HIV, tuberculosis and malaria are infections of huge
global burden, and priority areas for WHO [23] and as
well as the Global Fund, which has an annual budget of
around US$4 billion and collaborates with local, national
and international entities from the public, private and
Figure 1 Annual research investment for HIV, tuberculosis and malaria.
Figure 2 Annual publication numbers for HIV, tuberculosis and malaria.
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philanthropic sector with the aim of addressing and
greatly reducing the impact of these diseases in the
countries of highest burden [24]. Given the burden and
international focus, the significant level of research in-
vestment is important and the extent of the publications
and resultant citations unsurprising. However, funders
and policymakers need to know how well their invest-
ments are performing and quantifications of the num-
bers and usefulness of the published outputs are an
important measure of the impact and quality of research.
The metrics developed herein highlight the more effi-
cient performance of tuberculosis investments and
(more generally) public health research, and will be of
interest to the funding agencies and academic and
clinical institutions which seek to engage in the highest-
quality and best-performing research. It is also import-
ant that the large volume of knowledge generated by the
research and disseminated by the publications is made
clearly available to those involved in decision making re-
garding future funding priorities and more immediate
considerations for policy and implementation.
The approach described herein covers three important
disease areas, but it would be useful for future work to con-
sider other infectious diseases and to systematically analyse
investments and publications in non-communicable disease
research. The investment dataset does not consider private
sector investments, which may particularly impact upon
the metrics used here for phase I–III trials and for product
development research in these infections.
As journal requirements and publication databases
evolve, it will become increasingly possible to link individ-
ual investment and published outputs via grant reference
numbers and name of the agency sponsoring the research.
This will provide the ability to generate more precise met-
rics of the relationship between investment and publica-
tions and citations. There is also the possibility for future
Figure 3 Annual citations arising from publications relating to HIV, tuberculosis and malaria.
Table 2 Relative investment in type of science for HIV, tuberculosis and malaria research, as described by a ‘UK pound per
publication’ metric
Preclinical Phase I–III Product development Public health Total
HIV
Funding 1997–2010 £220,563,052 £111,316,004 £23,783,625 £160,119,168 £515,781,849
Publications 1997–2013 1,832 341 284 5,866 8,323
Pound per publication £120,395 £326,440 £83,745 £27,296 £61,971
Tuberculosis
Funding 1997–2010 £96,477,706 £11,605,445 £20,172,857 £39,735,452 £167,991,460
Publications 1997–2013 1,275 62 193 1,784 3,314
Pound per publication £75,669 £187,185 £104,523 £22,273 £50,691
Malaria
Funding 1997–2010 £202,459,316 £9,920,472 £12,839,850 £156,302,225 £381,521,863
Publications 1997–2013 2,112 164 138 1,624 4,038
Pound per publication £95,861 £60,491 £93,042 £96,245 £94,483
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work to consider published outputs by individual journal
and journal metrics. Other research has suggested that the
infectious disease content of the Lancet and New England
Journal of Medicine journals consists of up to 35% for
HIV and tuberculosis combined and 65% for all other in-
fections [6]; therefore, the relative importance of each dis-
ease area for funders and publishers would be important
to assess. Alongside the ResIn study [15], other research
has highlighted the importance of the United Kingdom in-
fectious disease research portfolio [25], and also the publi-
cation record of United Kingdom authors [4]. Funders
such as the Wellcome Trust also use bibliometric analyses
to assess their portfolio of studies [26]. Whilst detailed
and informative, the disadvantage of these reports is that
they focus solely on a single funder and each funder uses
different criteria to analyse their work; one strength of this
paper, and the ResIn study as a whole, is the unified ap-
proach across funders and disease areas, allowing simul-
taneous comparison of multiple awarding bodies.
The analysis in this study used data from one compre-
hensive publications database (Scopus) and inclusion of
data from other databases may have modified the results
as the content of each database is slightly different [ 27].
Categorisation of both investments and publications is
necessarily a pragmatic process and open to subjectivity,
though the rigour of the process is strengthened by the
cross-checks of random samples of data by a second au-
thor. We made pragmatic decisions when applying our
methodology – (1) that investments across 1997–2010
would publish most of their papers during 1997–2013;
(2) that only including first or last authors from a United
Kingdom institution would be a suitable measure of sig-
nificant United Kingdom involvement and therefore
likely to have received research funding. It is difficult to
estimate how many papers have been excluded, or
included, in error via these methods. Due to small
numbers, we do not anticipate a significant impact of
any retrospective reclassification of the cross-disciplinary
category by type of science in the 1997–2010 data. Indi-
vidual publications were assumed to be of equal impact
and not controlled for by journal impact factor or any
other publication or journal metric or weighting.
Conclusions
The analyses reported herein suggest that tuberculosis is
the best-performing disease area in terms of public and
philanthropic research investment and publication and
citation productivity, and public health is generally the
type of science that is most prolific. These investments
and publications generate great amounts of knowledge,
and the analyses we report here can inform the thinking
and priority-setting of policymakers such as WHO, na-
tional and international funding agencies, and the aca-
demic and clinical institutions which carry out research.
The ResIn study [15] has secured funding from the Bill and
Melinda Gates Foundation to carry out systematic analyses
on investments and publications in infectious diseases in
the G20 countries and so extended datasets will become
available for open collaboration across 2016 and 2017.
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